BBI Solutions launches a fully validated human recombinant Cystatin C antigen

Aug. 27, 2014

BBI Solutions has launched a new, fully validated recombinant Cystatin C antigen. Company representatives say that it offers the following benefits: It eliminates potential interferences from other proteins or contaminants due to high purity and low bioburden; it demonstrates excellent recovery compared to native Cystatin C; and it ensures supply sustainability with a recombinant product, not dependent on a biological raw material.

Cystatin C is primarily used as a diagnostic marker for kidney function; routine kidney function tests measure serum creatinine, urea, and glomular filtration rate (GFR). Serum Cystatin C is measured as part of the GFR test, as it is quicker and easier that traditional techniques of collecting urine samples over a 24-hour period. It has also been shown not be affected by age, gender, and body weight of the patient.

BBI Solutions manufactures raw materials and finished test platforms for the in-vitro diagnostics market. Its range of raw materials includes human antigens, antibodies, serum and plasma products, and clinical chemistry enzymes. The company also manufactures labels for lateral flow, ELISA assay, and biosensors, including gold nanoparticles, and glucose oxidase. Learn more about products offered by BBI Solutions.

Read more